Otezla® (apremilast) is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.

*Certain restrictions apply; eligibility not based on income, must be 18 years or older. This offer is not valid for persons eligible for reimbursement of this product, in whole or in part under Medicaid, Medicare, or similar state or federal programs. Offer not valid for cash-paying patients. People who are not eligible can call 1-844-4OTEZLA to discuss other financial assistance opportunities.

Please see Important Safety Information presented throughout this brochure and Full Prescribing Information here.
*Ensure your patient has received a sample Starter Pack prior to enrolling. To receive a free bridge supply of Otezla, patients must have an on-label diagnosis. Patients in Massachusetts are not eligible to receive bridge.† Patients that do not receive a sample Starter Pack will only receive Otezla after insurance approval.

Starting with an in-office sample:

**Otezla® (apremilast) 30 mg Starter Pack**
- 2 weeks of medication, including 5 days of titration doses

**Otezla 30 mg Bridge Pack**
- Commercial patients denied or waiting for coverage can receive a free supply of Otezla for up to 3 years*

Starting with the specialty pharmacy†:

**Otezla 30 mg 28-Day Pack**
- Includes 5 days of titration doses and additional maintenance doses if Starter Pack is not provided in-office

**Otezla 30 mg 30-Day Supply**
- Maintenance doses for patients who have received benefit verification

Please see Important Safety Information on page 6.
Otezla is an oral, non-biologic therapy

Treatment begins with a 5-day titration period. This is intended to reduce common gastrointestinal side effects

- Once the titration is complete, patients should take one pill in the morning and one pill at night
- Patients should not crush, split, or chew the tablet

**Otezla 30 mg Starter Pack**

Dosage should be reduced to 30 mg once daily in patients with severe renal impairment¹*

- For initial dosage titration, it is recommended that Otezla® (apremilast) be titrated using only the AM schedule and the PM doses skipped
- From day 6 on, the dose of Otezla is 30 mg once daily

*Creatine clearance (CrCl) <30mL/min estimated by the Cockcroft-Gault equation.

**SELECTED SAFETY INFORMATION**

**Contraindications**

- Otezla® (apremilast) is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation

**Warnings and Precautions**

- Diarrhea, Nausea and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting

Please see Important Safety Information on page 6.
Before starting treatment:

- **Let your patients know what to expect.** This may help them start and stay on treatment.
- **Review the benefits and risks of Otezla® (apremilast) with your patient,** including the most common adverse reactions with Otezla.
- **Discuss dosing and titration** to ensure they understand how to take Otezla.
- **Let your patients know about support services,** such as the $0 co-pay program*.

The Full Prescribing Information for Otezla has no requirement for routine laboratory monitoring\(^1\)

*Certain restrictions apply; eligibility not based on income, must be 18 years or older. This offer is not valid for persons eligible for reimbursement of this product, in whole or in part under Medicaid, Medicare, or similar state or federal programs. Offer not valid for cash-paying patients. People who are not eligible can call 1-844-4OTEZLA to discuss other financial assistance opportunities.

**Staying on treatment**

To ensure the treatment process runs as smoothly as possible, after the initial 5-day titration, remind your patients to:

- **Take one 30-mg pill in the morning and one 30-mg pill at night**\(^1\)
- **Keep the Otezla bottle where they can see it so that they remember to take it every day**
- **Connect taking their medication to something they do each day, such as brushing their teeth**

\(^1\)Otezla dosage should be reduced in patients with severe renal impairment (creatinine clearance less than 30 mL/min); for details, see Dosage and Administration, Section 2, in the Full Prescribing Information.

**Selected Safety Information**

**Warnings and Precautions (cont’d)**

- **Depression:** Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur.
- **Psoriasis:** Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.3% (12/920) of patients reported depression compared to 0.4% (2/506) on placebo; Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide.

Please see Important Safety Information on page 6.
Your patients may qualify to get Otezla for $0 per month*

Eligible patients on certain prescription plans can get Otezla® (apremilast) for no out-of-pocket cost with the $0 co-pay offer through SupportPlus™

*Certain restrictions apply; eligibility not based on income, must be 18 years or older. This offer is not valid for persons eligible for reimbursement of this product, in whole or in part under Medicaid, Medicare, or similar state or federal programs. Offer not valid for cash-paying patients. People who are not eligible can call 1-844-4OTEZLA to discuss other financial assistance opportunities.

Selected Safety Information

Warnings and Precautions (cont’d)

- **Psoriatic Arthritis:** Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.0% (10/998) reported depression or depressed mood compared to 0.8% (4/495) treated with placebo. Suicidal ideation and behavior was observed in 0.2% (3/1441) of patients on Otezla, compared to none in placebo treated patients. Depression was reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo treated patients (0/495). Two patients who received placebo committed suicide compared to none on Otezla.

- **Weight Decrease:** Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla
  - **Psoriasis:** Body weight loss of 5-10% occurred in 12% (96/784) of patients treated with Otezla and in 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with Otezla compared to 1% (3/382) of patients treated with placebo
  - **Psoriatic Arthritis:** Body weight loss of 5-10% was reported in 10% of patients taking Otezla and in 3.3% of patients taking placebo

For updated news and offers, join Otezla ProPlus™ today! Visit Otezlapro.com to sign up

Please see Important Safety Information on page 6.
INDICATIONS
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

IMPORTANT SAFETY INFORMATION
Contraindications
- Otezla® (apremilast) is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation.

Warnings and Precautions
- Diarrhea, Nausea and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting.

- Depression: Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur.
  - Psoriasis: Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.3% (12/920) of patients reported depression compared to 0.4% (2/506) on placebo; Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide.
  - Psoriatic Arthritis: Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.0% (10/998) reported depression or depressed mood compared to 0.8% (4/495) treated with placebo. Suicidal ideation and behavior was observed in 0.2% (3/1441) of patients on Otezla, compared to none in placebo treated patients. Depression was reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo treated patients (0/495). Two patients who received placebo committed suicide compared to none on Otezla.

- Weight Decrease: Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla.
  - Psoriasis: Body weight loss of 5-10% occurred in 12% (96/784) of patients treated with Otezla and 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with Otezla compared to 1% (3/382) of patients treated with placebo.
  - Psoriatic Arthritis: Body weight loss of 5-10% was reported in 10% of patients taking Otezla and in 3.3% of patients taking placebo.

- Drug Interactions: Apremilast exposure was decreased when Otezla was co-administered with rifamipin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended.

Adverse Reactions
- Psoriasis: Adverse reactions reported in ≥5% of patients were (Otezla%, placebo%): diarrhea (17, 6), nausea (11, 7), upper respiratory tract infection (9, 6), tension headache (8, 4), and headache (6, 4).
- Psoriatic Arthritis: Adverse reactions reported in at least 2% of patients taking Otezla, that occurred at a frequency at least 1% higher than that observed in patients taking placebo, up to 16 weeks (after the initial 5-day titration), were (Otezla%, placebo%): diarrhea (7.7, 1.6); nausea (8.9, 3.1); headache (5.9, 2.2); upper respiratory tract infection (3.9, 1.8); vomiting (3.2, 0.4); nasopharyngitis (2.6, 1.6); upper abdominal pain (2.0, 0.2).

Use in Specific Populations
- Pregnancy and Nursing Mothers: Otezla is Pregnancy Category C; it has not been studied in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether apremilast or its metabolites are present in human milk. Caution should be exercised when Otezla is administered to a nursing woman.
- Renal Impairment: Otezla dosage should be reduced in patients with severe renal impairment (creatinine clearance less than 30 mL/min); for details, see Dosage and Administration, Section 2, in the Full Prescribing Information.

Please click here for Full Prescribing Information.
For more information about Otezla, visit Otezlapro.com.


Otezla® is a registered trademark of Celgene Corporation. © 2017 Celgene Corporation 08/17 USII-APR170293